Navigation Links
Medivir Interim Report, 1 January - 30 September 2010
Date:10/22/2010

count); s.linkTrackVars='eVar3,prop15,prop16'; s.linkTrackEvents='None'; s.eVar3=s.prop16; s.prop15='Test'; //Newsrelease id s.prop16='CrowdFactory_Share'; s.tl(this,'o', 'CrowdFactory_Share');*/ var s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15,prop16,prop49,events';s.linkTrackEvents='event12';s.prop5='share it release';s.eVar3=s.prop5; s.prop15='105512033';s.prop16='CrowdFactory_Share';s.prop5+='_'+s.prop16;s.prop49=s.pageName;s.events='event12';s.tl(this,'o','CrowdFactory_Share'); }); cf_jq(".cf_dialog_footer button").live("mouseup", function (){ var socialText = this.innerHTML.replace("Post to ", ""); /*s.linkTrackVars='eVar3,prop15,prop16'; s.linkTrackEvents='None'; s.prop16='CrowdFactory_'+socialText; s.eVar3=s.prop16; s.prop15='Test'; //Newsrelease id s.tl(this,'o', 'CrowdFactory_'+socialText);*/ var s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15,prop16,prop49,events';s.linkTrackEvents='event12';s.prop5='share it release';s.eVar3=s.prop5; s.prop15='105512033';s.prop16='CrowdFactory_'+socialText;s.prop5+='_'+s.prop16;s.prop49=s.pageName;s.events='event12';s.tl(this,'o','CrowdFactory_'+socialText); }); });  

HUDDINGE, Sweden, October 22, 2010 /PRNewswire/ -- Medivir AB (OMX: MVIR), a research-based specialty pharmaceutical company focused on infectious diseases, is publishing its interim report today for the period covering 1 January - 30 September and a business update for the third quarter 2010.

Financial Highlights 1 January - 30 September - Consolidated net sales were SEK 54.7 (24.5) m. - The consolidated profit/loss for the period was SEK -77.6 (-93.0) m. - Earnings per share for the period were SEK -3.30 (-4.46). - Cash flow from operating activities was SEK -35.0 (-104.8) m. - Cash and cash equivalents and investments in securities etc. at the end of the period were SEK 421.8 (176.1) m. Third Quarter Operational Highlights - Positive phase 2b interim PILLAR data presented in July on TMC435, Medivir's lead deve
'/>"/>

SOURCE Medivir AB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 ... today announced that it has taken an exclusive worldwide ... FScan Ltd, a Durham University ... Pharma will pay an upfront fee, development and commercial ... Pharma has also taken an option for additional exclusive ...
(Date:7/28/2014)... Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH ), today announced ... June 30, 2014. Net loss for the ... to $8.3 million for the same period in 2013. The ... decrease in interest expense in the current period.  ... 2014 was $15.2 million, compared with net loss of $15.9 ...
(Date:7/28/2014)... YORK , July 28, 2014 Reportbuyer.com ... Global Bone Densitometers Market 2014-2018 ... A bone densitometry scan is a special type of ... a bone. It is used primarily to detect osteopenia ... low and the risk of fractures is high. The ...
Breaking Medicine Technology:Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 2Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 2Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 4Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 5Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 6Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 7Global Bone Densitometers Market 2014-2018 2Global Bone Densitometers Market 2014-2018 3Global Bone Densitometers Market 2014-2018 4Global Bone Densitometers Market 2014-2018 5
... MonoSol Rx, LLC ("MonoSol Rx"), the developer of PharmFilm® ... Inc., a wholly-owned subsidiary of Reckitt Benckiser Group plc ... market adoption of Suboxone® (buprenorphine HCl/naloxone HCl dihydrate) sublingual ... announcement of full-year 2010 financial results. ...
... Feb. 22, 2011 Prasco Laboratories ... supply agreement with Shire US Manufacturing, Inc. for ... Prasco, LLC is prepared to market the authorized ... Shire,s request, immediately upon any entrance into the ...
Cached Medicine Technology:MonoSol Rx, LLC Announces Suboxone Sublingual Film Achieves 25% Share of Total U.S. Suboxone Market Volume at Year-End 2010 2MonoSol Rx, LLC Announces Suboxone Sublingual Film Achieves 25% Share of Total U.S. Suboxone Market Volume at Year-End 2010 3
(Date:7/29/2014)... New Haven, CT (PRWEB) July 29, 2014 ... head up its Client Services Operation. , Christina Upton, ... been named Director of Client Services responsible for managing ... , Client Services is at the center of all ... the most well-known brands in the world . The ...
(Date:7/29/2014)... 1WorldSync announces B. Braun Melsungen AG, ... utilize the Global Data Synchronization Network™ (GDSN®) standard ... product information with the U.S. Food and Drug ... global supply chain. Holger Clobes, Head of Global ... Braun serves customers in 61 countries, among others ...
(Date:7/29/2014)... Collierville, TN (PRWEB) July 29, 2014 ... to the reimbursement model of all hospitals. Studies show ... tsunami.[1] One simple, easy, low cost tool that ... organizational performance by 20 to 25%. , Their secret? ... to one anther at the end of an operational ...
(Date:7/29/2014)... Doheny HealthDay Reporter , MONDAY, ... risk of cardiovascular disease may be able to take hormone ... harming their hearts, according to a new study. Previous ... replacement therapy had harmful effects on the heart. But, many ... treatments, and much further past menopause. In this ...
(Date:7/29/2014)... San Francisco, California (PRWEB) July 29, 2014 ... to reach USD 9,542.3 million by 2020, growing at ... according to a new study by Grand View Research, ... acceptance of these devices by the geriatric population, along ... are some of the major drivers of this market. ...
Breaking Medicine News(10 mins):Health News:CRN International Names New Director to Lead Client Services Department 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:Early Hormone Therapy May Be Safe for Women's Hearts 2Health News:Early Hormone Therapy May Be Safe for Women's Hearts 3Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 2Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 3Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 4Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 5Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 6
... Human Services reported that very little precautionary measures can be ... flu) // . The infection in humans is actually caused ... ,Hence to prevent the global pandemic it has issued various ... a global pandemic. The government says that as such ...
... Guarraci, an assistance professor of psychology at south-western university and ... has a greater effect on the sexual behaviour of female ... and is among the first to determine the effects of ... also probes into the relationship between caffeine and sex. ...
... press that all the medical expenditures of pregnant women will be ... ,This plan is introduced mainly to ensure proper ... six months this plan will add $5 million to the annual ... the amount of expenditure of the rural women by $18. The ...
... of lives ever year. The need the organ, kidney is on ... ,Of all the organ transplantations done, kidney transplantation accounts ... sudden fall in the number of people who come forward to ... of the patients to undergo kidney transplants has widened to more ...
... Science Museum in London has found a unique way to help ... people the much-needed dose of light // . ,The ... of dark winter days. ,Up to 500,000 people, a ... seasonal affective disorder. SAD is more common in the northern ...
... an 8% increase in its share, following approval of Vivagel ... of HIV. // The company even signed a $20 ... and Infectious Diseases, an integral part of the National Institute ... for the prevention of HIV infection. The FDA recognizes the ...
Cached Medicine News:Health News:Starpharma Develops New Gel (Vivagel) To Prevent HIV Transmission 2
The Advance revision knee system was designed to address the unpredictable nature of revision knee arthroplasty by providing a wide variety of implant and instrument options....
... CRA femoral component is intended for ... and varus/valgus ligament stability, yet require ... inadequate bone stock. The NexGen CRA ... PMMA precoat surface. This device is ...
... manufacturers focus attention on implant design, one ... Profix Total Knee System seeks to establish ... system and the tools to implant them. ... recognized for innovation in total knee instrumentation, ...
Cruciate retaining, posterior stabilized and constrained components....
Medicine Products: